TNSN98059A1 - Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant. - Google Patents

Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant.

Info

Publication number
TNSN98059A1
TNSN98059A1 TNTNSN98059A TNSN98059A TNSN98059A1 TN SN98059 A1 TNSN98059 A1 TN SN98059A1 TN TNSN98059 A TNTNSN98059 A TN TNSN98059A TN SN98059 A TNSN98059 A TN SN98059A TN SN98059 A1 TNSN98059 A1 TN SN98059A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical compositions
compositions containing
inflammatory
same
inhibitor compounds
Prior art date
Application number
TNTNSN98059A
Other languages
English (en)
French (fr)
Inventor
Marie Lundy Kristin
Paul Ricketts Anthony
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN98059A1 publication Critical patent/TNSN98059A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
TNTNSN98059A 1997-05-05 1998-05-04 Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant. TNSN98059A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
TNSN98059A1 true TNSN98059A1 (fr) 2005-03-15

Family

ID=21939053

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98059A TNSN98059A1 (fr) 1997-05-05 1998-05-04 Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant.

Country Status (32)

Country Link
EP (1) EP0988034A1 (ko)
JP (1) JP2000513020A (ko)
KR (2) KR20010012300A (ko)
CN (1) CN1255059A (ko)
AP (1) AP9801234A0 (ko)
AR (2) AR011726A1 (ko)
AU (1) AU6932198A (ko)
BG (1) BG103852A (ko)
BR (1) BR9808720A (ko)
CA (1) CA2288759A1 (ko)
DZ (1) DZ2479A1 (ko)
EA (1) EA003696B1 (ko)
GT (1) GT199800063A (ko)
HR (1) HRP980244A2 (ko)
HU (1) HUP0001286A3 (ko)
ID (1) ID21311A (ko)
IL (1) IL132570A0 (ko)
IS (1) IS5220A (ko)
MA (1) MA26491A1 (ko)
NO (1) NO995389L (ko)
NZ (1) NZ500183A (ko)
OA (1) OA11213A (ko)
PA (1) PA8450601A1 (ko)
PE (1) PE72599A1 (ko)
PL (1) PL337003A1 (ko)
SK (1) SK148199A3 (ko)
TN (1) TNSN98059A1 (ko)
TW (1) TW590773B (ko)
UY (1) UY24989A1 (ko)
WO (1) WO1998050033A1 (ko)
YU (1) YU55899A (ko)
ZA (1) ZA983722B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
US6506785B2 (en) * 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
CA2347365A1 (en) * 1998-10-23 2000-05-04 Merck Frosst Canada & Co. Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
DE60023119T2 (de) * 1999-03-10 2006-07-20 G.D. Searle Llc Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere
WO2001034204A1 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001087343A2 (en) * 2000-05-15 2001-11-22 Merck Frosst Canada & Co. Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
PL206268B1 (pl) 2000-06-13 2010-07-30 Wyethwyeth Kompozycja przeciwbólowa i/lub przeciwzapalna oraz jej zastosowanie
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
EP1307585B1 (en) 2000-08-07 2009-01-21 Vanderbilt University Compositions and methods for detecting and quantifying cox-2 activity and 2-arachidonylglycerol metabolites
WO2003007875A2 (en) * 2001-07-16 2003-01-30 Hoegestaett Edward Compounds with analgesic, antipyretic and/or anti-inflammatory activity
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
MXPA06001288A (es) * 2003-07-31 2006-04-11 Upjohn Co Formulacion dispersable de un agente anti-inflamatorio.
EA200702280A1 (ru) * 2005-05-20 2008-04-28 Пфайзер Лимитед Синергические комбинации
JP2010523554A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド タクロリムスの医薬組成物
US8951570B2 (en) 2007-04-26 2015-02-10 Sigmoid Pharma Limited Manufacture of multiple minicapsules
GB2483815B (en) 2009-05-18 2013-12-25 Sigmoid Pharma Ltd Composition comprising oil drops
CN107582526A (zh) 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN105939713A (zh) 2014-03-06 2016-09-14 阿莱塔纳治疗学股份有限公司 格拉匹纶组合物及其使用方法
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin
WO2016112312A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals
WO2021195346A1 (en) * 2020-03-25 2021-09-30 Sri International Lipoxygenase inhibitors
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions

Also Published As

Publication number Publication date
HUP0001286A2 (hu) 2000-11-28
GT199800063A (es) 1999-10-26
CA2288759A1 (en) 1998-11-12
WO1998050033A1 (en) 1998-11-12
PL337003A1 (en) 2000-07-31
EA199900895A1 (ru) 2000-06-26
NZ500183A (en) 2002-04-26
ZA983722B (en) 1999-11-04
KR20010012300A (ko) 2001-02-15
DZ2479A1 (fr) 2003-02-01
AR011726A1 (es) 2000-08-30
AP9801234A0 (en) 1999-11-04
PE72599A1 (es) 1999-08-12
PA8450601A1 (es) 2000-05-24
MA26491A1 (fr) 2004-12-20
NO995389D0 (no) 1999-11-04
EA003696B1 (ru) 2003-08-28
OA11213A (en) 2003-07-14
SK148199A3 (en) 2001-09-11
IS5220A (is) 1999-10-19
AR039628A2 (es) 2005-03-02
YU55899A (sh) 2003-08-29
KR20040004406A (ko) 2004-01-13
UY24989A1 (es) 2001-10-25
AU6932198A (en) 1998-11-27
HUP0001286A3 (en) 2000-12-28
CN1255059A (zh) 2000-05-31
TW590773B (en) 2004-06-11
EP0988034A1 (en) 2000-03-29
NO995389L (no) 2000-01-04
ID21311A (id) 1999-05-20
HRP980244A2 (en) 1999-02-28
JP2000513020A (ja) 2000-10-03
BG103852A (en) 2000-06-30
BR9808720A (pt) 2000-07-11
IL132570A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
TNSN98059A1 (fr) Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant.
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
GB2303629B (en) Hydroxamic acids and their use as metalloproteinase inhibitors
MA24193A1 (fr) Procedes pour la preparation de conjugue peg-ifn alpha physiologiquement actif, et pour la preparation de compositions pharmaceutiques le contenant et leur utilisation
HUP0004396A2 (hu) A lipoprotein-oxidáció gátlására szolgáló, hatóanyagként hidroxilezett koleszterincsökkentő szert tartalmazó gyógyszerkészítmények
IL119627A0 (en) Controlled-release pharmaceutical preparations
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN99133A1 (fr) Procede perfectionne pour la preparation de bases de schiff et produits ainsi obtenus
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
ITMI930582A1 (it) Composizione farmeceutiche ad attivita' analgesica
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
HUP0301128A2 (hu) 5-Metil-2-(2'-kloro-6'-fluoranilino)-fenilecetsavat tartalmazó gyógyszerkészítmények ciklooxigenáz-2-vel kapcsolatos betegségek kezelésére és alkalmazásuk
ATE458471T1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
DE69706241D1 (de) Pharmazeutische Zusammensetzung zur Behandlung der Leukämie enthaltend 9-cis-Retinoinsäure-alpha-Tocopherolester
ATE280575T1 (de) Transdermales therapeutisches system zur anwendung von candesartan
TNSN99154A1 (fr) Compositions pharmaceutiques comprenant des inhibiteurs de nos, leur preparation et leur utilisation
BE902055A (fr) Preparations pharmaceutiques.
IL110888A (en) Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound
TNSN99199A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc A LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION
TNSN96025A1 (fr) Nouvelle presentation pharmaceutique a voie buccale
FR2823440B1 (fr) Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans
TH13515EX (th) สารที่ใช้เป็นยาสำหรับรักษาอาการอักเสบหรือบรรเทาอาการปวด